Safety and Effectiveness of Agilus (Hyaluronic Acid) for Ankle Osteoarthritis

NCT ID: NCT00642382

Last Updated: 2017-08-17

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

NA

Total Enrollment

17 participants

Study Classification

INTERVENTIONAL

Study Start Date

2008-04-30

Study Completion Date

2008-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to determine whether Agilus is safe and effective in the treatment of mild to moderate ankle osteoarthritis.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The objective of this study is to compare the safety and effectiveness of Agilus to a saline injection (control) in the treatment of mild to moderate ankle osteoarthritis. This is a multi-center, randomized, double blind, saline controlled, prospective study with two (2) treatment groups. The active group will receive one injection of Agilus per week for three consecutive weeks for a total of three injections. The control group will receive one injection of normal saline per week for three consecutive weeks for a total of three injections. Follow up visits will occur at 4 weeks, 12 weeks and 26 weeks following the third injection.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

OSTEOARTHRITIS

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

TRIPLE

Participants Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Active

Agilus (Hyaluronic Acid)

Group Type ACTIVE_COMPARATOR

Agilus

Intervention Type DEVICE

Hyaluronic acid (Agilus)given by an intra-articular injection into the ankle for a total of 3 injections for 3 consecutive weeks.

Control

Normal Saline

Group Type PLACEBO_COMPARATOR

Normal saline

Intervention Type DEVICE

Normal Saline given by an intra-operative injection into the ankle for a total of 3 injections for 3 consecutive weeks.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Agilus

Hyaluronic acid (Agilus)given by an intra-articular injection into the ankle for a total of 3 injections for 3 consecutive weeks.

Intervention Type DEVICE

Normal saline

Normal Saline given by an intra-operative injection into the ankle for a total of 3 injections for 3 consecutive weeks.

Intervention Type DEVICE

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Hyaluronic Acid

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* 18 years or older
* Chronic, unilateral ankle pain(i.e., in only one ankle) for at least 6 months
* Diagnosis of ankle OA confirmed by radiographs (X-ray)and clinical exam
* Are normally active, without aid of mobility devices(such as crutch, walker or cane)

Exclusion Criteria

* Have used oral steroids within 30 days (inhaled or topical steroids are acceptable)
* Have received intra-articular injections of hyaluronic acid in any joint in the last 9 months
* Have received steroid injections in any joint in last 3 months
* Have had previous surgery or arthroscopy on the affected ankle in the last 12 months
Minimum Eligible Age

18 Years

Maximum Eligible Age

95 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Cartiva, Inc.

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Judith Baumhauer, MD

Role: PRINCIPAL_INVESTIGATOR

University of Rochester

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Orthopaedic Associates of Hartford

Farmington, Connecticut, United States

Site Status

Pinnacle Research

Royal Palm Beach, Florida, United States

Site Status

Rush University Medical Center

Chicago, Illinois, United States

Site Status

Institute For Foot and Ankle Reconstruction At Mercy

Baltimore, Maryland, United States

Site Status

Greater Chesapeake Orthopaedic Association

Baltimore, Maryland, United States

Site Status

Brigham Foot and Ankle Center

Boston, Massachusetts, United States

Site Status

Orthopedic Associates of Grand Rapids

Grand Rapids, Michigan, United States

Site Status

Minnesota Sports Medicine

Eden Prairie, Minnesota, United States

Site Status

University of Missouri

Columbia, Missouri, United States

Site Status

Desert Orthopaedic Center

Las Vegas, Nevada, United States

Site Status

Dartmouth Hitchcock Medical Center

Lebanon, New Hampshire, United States

Site Status

UMDNJ

Newark, New Jersey, United States

Site Status

University of Rochester

Rochester, New York, United States

Site Status

Orthocarolina

Charlotte, North Carolina, United States

Site Status

Orthopedic Foot and Ankle Center

Columbus, Ohio, United States

Site Status

University of Pennsylvania

Philadelphia, Pennsylvania, United States

Site Status

Rhode Island Hospital

Providence, Rhode Island, United States

Site Status

Bone and Joint Clinic Houston

Houston, Texas, United States

Site Status

University of Texas Health Science Center At Houston

Houston, Texas, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

CMI-CP-Ankle-001

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

The MONOVISC Hip Osteoarthritis Study
NCT02698865 TERMINATED PHASE3